Esophageal cancer: The role of integrated CT-PET in initial staging and response assessment after preoperative therapy

Journal of Thoracic Imaging

Volumn 21, Issue 2, 2006, Pages 137-145

  Munden, Reginald F ^a   Macapinlac, Homer A ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Esophageal cancer; Esophageal cancer staging; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; CANCER INFILTRATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LYMPH NODE METASTASIS; PARAAORTIC LYMPH NODE; PREOPERATIVE EVALUATION; TISSUE SECTION; TREATMENT RESPONSE;

EID: 33745216467     PISSN: 08835993     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005382-200605000-00005     Document Type: Conference Paper

References (65)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. C A Cancer J Clin. 2006;2:106-130.
2. Swisher SG, Hunt KK, Holmes EC, et al. Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg. 1995;6:609-614.
3. Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;8:845-857.
4. Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988;2:242-248.
5. Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;1:120-127.
6. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;7:462-467.
7. Donington JS, Miller DL, Allen MS, et al. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;4:631-636; discussion 36-37.
8. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;2:305-313.
9. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;6:1118-1123.
10. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;27:1979-1984.
11. Liberale G, Van Laethem JL, Gay F, et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol. 2004;9:942-947.
12. Rasanen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol. 2003;8:954-960.
13. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg. 2000;6:743-752.
14. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;18:3805-3812.
15. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
16. van Westreenen HL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005;1:54-61.
17. Beseth BD, Bedford R, Isacoff WH, et al. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg. 2000;9:827-831.
18. Jones DR, Parker LA Jr, Detterbeck FC, et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 1999;5:1026-1032.
19. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;6:1232-1241.
20. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology. 2005;3:841-851.
21. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;5:900-908.
22. Yang Q, Cleary KR, Yao JC, et al. Significance of postchemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004;1:38-43.
23. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol. 2003;5: 337-346.
24. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;3:361-368.
25. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;3:279-283.
26. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;3:428-432.
27. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;12:3058-3065.
28. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;3:300-309.
29. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;4:1053-1059.
30. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;11:882-887.
31. Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;3:770-776; discussion 76-77.
32. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg. 2002;9:1001-1006; discussion 06-07.
33. Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998;4:521-527.
34. Bar-Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005;8:918-924.
35. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg. 2003;4:938-944.
36. Greene F PD, Fleming ID, et al, editors. American Joint Commission on Cancer. 2002.
37. Demeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006;13:12-30.
38. Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am. 2000;3:471-485.
39. Heeren PA, van Westreenen HL, Geersing GJ, et al. Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. Endoscopy. 2004;11:966-971.
40. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am. 1995;3:537-547.
41. Rice TW, Blackstone EH, Adelstein DJ, et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg. 2003;5:1091-1102.
42. Hunerbein M, Ulmer C, Handke T, et al. Endosonography of upper gastrointestinal tract cancer on demand using miniprobes or endoscopic ultrasound. Surg Endosc. 2003;4:615-619.
43. Berger AC, Scott WJ. Noninvasive staging of esophageal carcinoma. J Surg Res. 2004;1:127-133.
44. Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005;1-9.
45. Petrillo R, Balzarini L, Bidoli P, et al. Esophageal squamous cell carcinoma: MRI evaluation of mediastinum. Gastrointest Radiol. 1990;4:275-278.
46. Kneist W, Schreckenberger M, Bartenstein P, et al. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg. 2003;10:1105-1112.
47. Heeren PA, Jager PL, Bongaerts F, et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med. 2004;6:980-987.
48. Romagnuolo J, Scott J, Hawes RH, et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc. 2002;6:648-654.
49. Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/ laparoscopy. Ann Thorac Surg. 2002;4:1026-1032.
50. Parmar KS, Zwischenberger JB, Reeves AL, et al. Clinical impact of endoscopic ultrasound-guided fine needle aspiration of celiac axis lymph nodes (M1a disease) in esophageal cancer. Ann Thorac Surg. 2002;3:916-920; discussion 20-21.
51. Eloubeidi MA, Wallace MB, Reed CE, et al. The utility of EUS and EUS-guided fine needle aspiration in detecting celiac lymph node metastasis in patients with esophageal cancer: a single-center experience. Gastrointest Endosc. 2001;6:714-719.
52. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;2:417-424.
53. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;4:1133-1136; discussion 36-37.
54. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 9319:1727-1733.
55. Eloubeidi MA, Wallace MB, Hoffman BJ, et al. Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg. 2001;1:212-219; discussion 19-20.
56. Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma. Am J Gastroenterol. 2001;9:2651-2656.
57. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;19:4330-4337.
58. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;5:810-817; discussion 17-20.
59. Brink I, Hentschel M, Bley TA, et al. Effects of neoadjuvant radiochemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;5:544-550.
60. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;8:1776-1785.
61. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;4:1152-1160; discussion 52-60.
62. Arslan N, Miller TR, Dehdashti F, et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4:301-310.
63. Nakamura R, Obara T, Katsuragawa S, et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med. 2002;4:181-186.
64. Bhargava P, Reich P, Alavi A, et al. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med. 2003;10:849-850.
65. Hautzel H, Muller-Gartner H. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med. 1997;1384-1386.